

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

PrecisionMed

RRID:SCR_010486

Type: Tool

Proper Citation

PrecisionMed (RRID:SCR_010486)

Resource Information

URL: <http://www.precisionmed.com/>

Proper Citation: PrecisionMed (RRID:SCR_010486)

Description: A biorepository of human biological material from healthy and diseased populations with a special focus on subjects with Alzheimer's disease, multiple sclerosis, Parkinson's disease and other neurological disorders. Data is collected longitudinally. PrecisionMed aims to facilitate research in genetics, drug discovery, biomarker research and molecular diagnostics. Materials collected include DNA, RNA, plasma and cerebrospinal fluid, among others.

Synonyms: Precision Med Inc., PrecisionMed: Human Biological Material

Resource Type: biomaterial supply resource, material resource, tissue bank

Keywords: csf, dna, rna, serum, plasma, alzheimer's disease, ad, mild cognitive impairment, mci, multiple sclerosis, ms, parkinson's disease, schizophrenia, pd, sz, cerebrospinal fluid, diseased, urine, csf cell pellets, paxgene, ffpe, research, biobank, biorepository, collection, human sample, healthy, diseased

Related Condition: Alzheimer's disease, Mild cognitive impairment, Multiple Sclerosis, Parkinson's disease, Schizophrenia

Availability: Available to the research community

Resource Name: PrecisionMed

Resource ID: SCR_010486

Alternate IDs: nlx_29853

Record Creation Time: 20220129T080259+0000

Record Last Update: 20260829T183004+0000

Ratings and Alerts

No rating or validation information has been found for PrecisionMed.

No alerts have been found for PrecisionMed.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sun S, et al. (2026) Toward Early Diagnosis and Therapeutic Discovery in CLN3 Disease: A Computational Biomarker Discovery Framework. medRxiv : the preprint server for health sciences.

Sheth U, et al. (2025) Measuring neurofilament light in human plasma and cerebrospinal fluid: a comparison of five analytical immunoassays. bioRxiv : the preprint server for biology.

Michaelis T, et al. (2025) Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis. Nature, 647(8091), 970.

Allam M, et al. (2024) Spatial immunophenotyping using multiplexed imaging of immune follicles in secondary lymphoid tissues. PNAS nexus, 3(8), pgae285.

Chen A, et al. (2024) Performance of SOBA-AD blood test in discriminating Alzheimer's disease patients from cognitively unimpaired controls in two independent cohorts. Scientific reports, 14(1), 7946.

Chaudhary S, et al. (2024) Dissecting the MUC5AC/ANXA2 signaling axis: implications for brain metastasis in lung adenocarcinoma. Experimental & molecular medicine, 56(6), 1450.

Sandoval C, et al. (2024) CSF complement proteins are elevated in prodromal to moderate Alzheimer's disease patients and are not altered by the anti-tau antibody semorinemab. Alzheimer's & dementia : the journal of the Alzheimer's Association, 20(11), 7940.

Phu Pham LH, et al. (2023) Assess Alzheimer's Disease via Plasma Extracellular Vesicle-derived mRNA. medRxiv : the preprint server for health sciences.

Gu??vremont D, et al. (2022) Plasma microRNA vary in association with the progression of Alzheimer's disease. Alzheimer's & dementia (Amsterdam, Netherlands), 14(1), e12251.

Triana-Baltzer G, et al. (2021) Development and validation of a high-sensitivity assay for measuring p217+tau in plasma. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 13(1), e12204.

Dhanwani R, et al. (2020) T Cell Responses to Neural Autoantigens Are Similar in Alzheimer's Disease Patients and Age-Matched Healthy Controls. *Frontiers in neuroscience*, 14, 874.

Rotunno MS, et al. (2020) Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease. *Scientific reports*, 10(1), 2479.

Lasseter HC, et al. (2020) Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson's disease. *Cytokine: X*, 2(2), 100027.

Setiadi AF, et al. (2019) IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. *Journal of neuroimmunology*, 332, 147.

Chan HN, et al. (2019) Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification. *Theranostics*, 9(10), 2939.

Dominy SS, et al. (2019) *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. *Science advances*, 5(1), eaau3333.

Otake K, et al. (2019) Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid. *BMC medical genomics*, 12(1), 7.

Toghi Eshghi S, et al. (2018) Quality assessment and interference detection in targeted mass spectrometry data using machine learning. *Clinical proteomics*, 15, 33.

Guiraud SP, et al. (2017) High-throughput and simultaneous quantitative analysis of homocysteine-methionine cycle metabolites and co-factors in blood plasma and cerebrospinal fluid by isotope dilution LC-MS/MS. *Analytical and bioanalytical chemistry*, 409(1), 295.

Oh-Nishi A, et al. (2016) A possible serologic biomarker for maternal immune activation-associated neurodevelopmental disorders found in the rat models. *Neuroscience research*, 113, 63.